Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.43 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6547004 | 0.98 | ESR1 (0.50) | ESR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2350960 | 0.88 | HTR2A (0.50) | ESR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6546231 | 0.87 | ESR1 (0.42) | ESR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| Diethylamine SCHEMBL8172450 | 0.87 | ESR1 (0.42) | ESR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6546848 | 0.86 | ESR1 (0.41) | ESR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6547345 | 0.84 | ESR1 (0.39) | ESR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| Benzylamine SCHEMBL10781356 | 0.84 | LOXL2 (0.52) | ESR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9656285 | 0.83 | ESR1 (0.50) | ESR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31538069 | 0.83 | ESR1 (0.50) | ESR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10781443 | 0.82 | MEN1 (0.45) | CHRM2DRD3ADRB2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | MUELLER ALAN L | 2006-06-29 | — | — | US | disclosed |
| US-6750244-B2 | NERVOUS SYSTEM DISORDERS | NPS PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-6211245-B1 | DRUGS FOR CONTROLLING CALCIUM MODULATORS | NPS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| US-6051610-A | COMPOUNDS USEFUL AS NEUROPROTECTANTS, ANTICONVULSANTS, ANXIOLYTICS, ANALGESICS, MUSCLE RELAXANTS OR ADJUVANTS TO GENERAL ANESTHETICS | NPS PHARMACEUTICALS, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-6017965-A | TREATING STROKE, HEAD TRAUMA, SPINAL CORD INJURY, SPINAL CORD ISCHEMIA, ISCHEMIA- OR HYPOXIA-INDUCED NERVE CELL DAMAGE, EPILEPSY, ANXIETY, NEUROPSYCHIATRIC OR COGNITIVE DEFICITS DUE TO ISCHEMIA OR HYPOXIA | NPS PHARMACEUTICALS, INC. (US) | 2000-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NCS1, ATP2A1, CACNA1D | ESR1 1098/4885CYP2D6 4442/4885SLC6A2 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.